Ardent Health Corporation (NYSE:ARDT) is a prominent player in the healthcare sector, providing a range of services across its network of hospitals and healthcare facilities. As ARDT prepares to release its quarterly earnings on March 4, 2026, analysts are predicting an earnings per share (EPS) of $0.34 and revenue of approximately $1.63 billion.
Despite these projections, ARDT is currently embroiled in a securities fraud class action lawsuit. The lawsuit, managed by Kahn Swick & Foti, LLC, is due to undisclosed collections problems that have led to a 33% decline in its stock value. Investors who purchased securities between July 18, 2024, and November 12, 2025, are encouraged to file lead plaintiff applications by March 9, 2026.
ARDT's financial metrics reveal a mixed picture. The company has a price-to-earnings (P/E) ratio of 6.45, indicating a relatively low valuation compared to its earnings. Its price-to-sales ratio is 0.21, meaning investors pay 21 cents for every dollar of sales. The enterprise value to sales ratio is 0.48, reflecting its valuation in relation to revenue.
The company's enterprise value to operating cash flow ratio stands at 8.28, suggesting a moderate valuation based on cash flow. ARDT's earnings yield is 15.50%, providing a measure of return on investment for shareholders. However, the debt-to-equity ratio of 1.84 indicates a significant reliance on debt in its capital structure.
ARDT's current ratio of 2.08 suggests a strong ability to cover short-term liabilities with short-term assets. As the company navigates its legal challenges, these financial metrics will be crucial for investors assessing its stability and potential for recovery.
